Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses alopecia areata occurring during Interferon Alpha-2b/Ribavirin therapy and reports no new clinical results.

This study reported that while lichen planus was not significantly linked to hepatitis C virus infection, pruritus, dry skin, and hair loss were more common in HCV patients post-interferon treatment.

A woman developed white patches on her skin and curly hair after hepatitis C treatment, likely due to the medication interferon alpha.

This study found that dermatological adverse events from interferon-alpha/ribavirin treatment for chronic hepatitis C are associated with factors like older age, pre-existing skin conditions, cirrhosis, and the use of pegylated interferon formulations.

This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.

This case report describes a rare instance of alopecia universalis occurring eight weeks after discontinuing pegylated interferon α and ribavirin therapy, highlighting the need for awareness among healthcare providers.

This report describes a case of alopecia universalis in a woman with hepatitis C linked to pegylated interferon alfa-2b and ribavirin therapy, with hair regrowth observed one year after discontinuation.

This case report describes irreversible alopecia universalis following discontinuation of Peg-IFN/RBV treatment for chronic hepatitis C, highlighting potential autoimmune side effects of interferon-based therapies.

This case report identified dystrophic anagen effluvium as a previously unreported dermatological side effect of PEG-INF-α-2a/RBV combination therapy in a patient with chronic hepatitis C infection.

This letter to the editor discusses excessive hair growth observed around local β-interferon injection sites for malignant melanoma but reports no new clinical results.

In this study conducted at Baqiyatullah Hospital, it was found that interferon beta (IFNβ) treatment in multiple sclerosis patients commonly led to skin complications, with injection site erythema being most frequent, and also increased hair loss severity.

Some patients lost hair after taking interferon alpha 2B, but it improved for some while still on the treatment and for others after stopping it.

This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.

This study found that 87% of patients with stage IIA and IIB melanoma treated with low-dose alpha-interferon reported cutaneous side effects, with the most common being hair loss.

This study demonstrated the expression of type 1 interferon-related proteins in inflammatory lesions of alopecia areata, showing a distinct distribution pattern compared to cicatricial alopecia.

This case study describes the successful use of recombinant feline interferon-omega in managing feline chronic gingivostomatitis syndrome in cats with type II diabetes, where long-acting corticosteroids are contraindicated.

This case study reports the first instance of irreversible alopecia universalis occurring during pegylated interferon-ribavirin therapy in a man with hepatitis C infection, without evidence of immunological or thyroid disorders.

In this report, a case of a bullous lesion developed at the injection site in a patient treated with PEG-IFN-α-2a for chronic hepatitis C was described.

In this study, 97% of patients undergoing pegylated interferon alfa2a and ribavirin therapy for chronic hepatitis C experienced one or more skin-related side effects, with hair loss being the most common.

This review discusses the involvement of type I interferons in skin autoimmune and inflammatory diseases but reports no new clinical results.

In this study, Typhonium flagelliforme leaf-ethanolic extract combined with natural interferon was observed to stabilize body weight, inhibit tumor growth, and reduce mitosis, angiogenesis, and certain protein expressions in carcinogen-induced tumors in female mice, suggesting potential antitumor effects.

This study observed that long-term recombinant interferon alpha-2b therapy was associated with considerable hair loss in some patients, indicated by a telogen effluvium pattern on trichograms.

This study observed that two patients treated with interferon α-2b and ribavirin for chronic hepatitis C experienced complete and reversible straightening of their natural curly hair, which recurred with treatment resumption.

In this study, pegylated interferon alfa-2b injections led to local cutaneous reactions, including cutaneous necrosis, in patients with hepatitis C and chronic myelocytic leukemia, requiring dose modifications or treatment withdrawal in some cases.

In this study, a patient with clinically amyopathic dermatomyositis experienced persistent skin issues despite treatment, highlighting questions about type I interferon's role in skin disorders and potential IFN-targeted therapies for cutaneous lupus erythematosus and dermatomyositis.

This study observed that inflammatory AIGA is associated with sweat duct inflammation and sweat coil atrophy, while non-inflammatory AIGA involves only sweat coil atrophy, suggesting distinct pathological features between the two.

This study found that patients taking hydroxychloroquine had a significantly higher likelihood of indeterminate QuantiFERON-TB Gold test results compared to those not on the medication, independent of other immunosuppressive drug use.

The study identified increased IL-24 expression in keratinocytes and fibroblasts exposed to particulate matter, contributing to skin aging by promoting conditions similar to age-related changes such as increased MMP1 expression and decreased type I collagen production.

This study found that knock-down of keratin 15 in various cell lines affected cell spreading, morphology, migration, differentiation, and proliferation, suggesting its role in maintaining the stem cell nature of keratinocytes.

In this study, researchers examined chronic hepatitis B patients and found that those undergoing interferon therapy reported higher quality of life than those on non-antiviral or nucleoside/nucleotide analogue treatments, despite potential side effects.